To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Imatinib treatment and Aβ… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Imatinib treatment and Aβ42 in humans.

Journal article
Authors Bob Olsson
Laurence Legros
François Guilhot
Kia Strömberg
James Smith
Frederick J Livesey
David H Wilson
Henrik Zetterberg
Kaj Blennow
Published in Alzheimer's & dementia : the journal of the Alzheimer's Association
Volume 10
Issue 5, supplement
Pages S374–S380
ISSN 1552-5279
Publication year 2014
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages S374–S380
Language en
Keywords Aβ42, Imatinib, Plasma, CML, Alzheimer's disease
Subject categories Neurochemistry


The first-line treatment in chronic myeloid leukemia (CML), imatinib, has been shown to decrease the production of amyloid-β (Aβ) in vitro and in animal studies. However, whether imatinib has this effect in humans is not known.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?